IMVIONIX
Stories
-
IMVIONIX acquires U.S. and Canadian rights to BEOVU
IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema.